First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

First-line sunvozertinib prolonged progression-free survival compared with chemotherapy, but overall survival remains unknown — the data were immature (39% maturity). In the phase 3 WU-KONG28 trial (n=324), median progression-free survival was 10.3 versus 7.5 months (HR 0.65; 95% CI 0.50-0.85; P<0.001), the objective response rate was 58.9% versus 31.1%, and median duration of response was 11.2 versus 7.1 months. The population was advanced non-small-cell lung cancer with EGFR exon 20 insertions, a subtype that responds poorly to older EGFR inhibitors. The cost: grade 3 or higher adverse events in 75.5% of patients versus 56.7% with chemotherapy, although no deaths were attributed to the drug.